GSK Reports Q3 Earnings Beat with Strong Specialty Medicines and HIV Sales Growth
GSK has reported third-quarter financial results that exceeded analyst expectations, posting a Non-GAAP EPS of £0.55, which beat estimates by £0.04. Total revenue reached £8.89 billion, representing a 4% year-over-year increase and surpassing projections by £50 million. The growth was driven primarily by strong performance in key therapeutic areas. Specialty Medicines sales rose 15% to £3.9 billion, while HIV sales grew 10% to reach £2.1 billion. Significant momentum was also seen in the Respiratory, Immunology & Inflammation sector (+21%) and Oncology (+23%), underscoring a diversified revenue stream.
Tickers: $GSK
Topics: earnings beat pharmaceuticals revenue growth specialty medicines
Read the full article at Seeking Alpha
Part of the story Edward Jones Reports Strong Q3 2026 Growth Driven by Advisory Assets and New Digital Solutions (22 articles)